Predicting Progression of STEC-HUS: Use of Shiga Toxin Subtype and Routine Laboratory Screening
Journal of the Pediatric Infectious Diseases Society · 08.04.2025 · 14 (4)
DOI: 10.1093/jpids/piaf022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, online erschienen am 01.03.2025. Verfasst von Lydia Maleknia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Kaiser Permanente Northern California, Oakland, CA, United States. Hauptthemen laut MEDLINE: Hemolytic-Uremic Syndrome, Shiga-Toxigenic Escherichia coli, Escherichia coli Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Graduate Medical Education, Kaiser Permanente Community Health Program.
Abstract (Originalsprache)
Background
Hemolytic uremic syndrome (HUS) is life-threatening sequelae of Shiga toxin-producing Escherichia coli (STEC) enteric infection. To address ambiguity in medical literature, we aimed to identify which STEC toxin profiles and clinical variables were at the highest risk of HUS progression to inform evidence-based screening guidelines.
Methods
This was a 5-year retrospective study of children aged <18 years with E. coli O157, Shiga toxin 1 (stx1), or Shiga toxin 2 (stx2)-positive stool. Demographics, clinical symptoms, laboratory studies, and HUS progression were abstracted from the electronic health record. Univariate and multivariable logistic regression identified variables associated with HUS.
Results
Of 1071 children with STEC, 55 were hospitalized with HUS (mean age 4.4 years [SD 3.7]). Predictors of HUS were age < 5 years and stool positive for E. coli O157 with stx2, or non-O157 stx2. No children of any age with O157 alone, O157 and stx1, or non-O157 stx1 and stx2 developed HUS. The prevalence of HUS with non-O157 stx1 alone was 0.2%. Vomiting, dehydration, abnormal blood counts, and chemistry were the only clinical variables associated with HUS.
Conclusion
We urge care management guidelines based on E. coli serotype and stx. All families of children with STEC should be counseled on the signs and symptoms of HUS and the steps to prevent dehydration; however, serial laboratory monitoring for HUS screening can be reserved for children at the highest risk for HUS. Given the substantial differences in HUS risk with stx2 as the main driver of HUS, we advocate that laboratories provide stx results to better inform anticipatory guidance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Kaiser Permanente Northern California, Oakland, CA, United States.
- Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States.
- Department of Graduate Medical Education, Kaiser Permanente Northern California, Oakland, CA, United States.
- Department of Pediatrics, Division of Infectious Diseases, Kaiser Permanente Northern California, San Francisco, CA, United States.
- The Permanente Medical Group, Oakland, CA, United States.
ORCID-Profile: Lydia Maleknia
Förderung
- Graduate Medical Education
- Kaiser Permanente Community Health Program
Zitieren
APA
Maleknia, L., Samiezade-Yazd, Z., Luu, X., Cranshaw, M., Weintraub, M. R., & Greenhow, T. L. (2025). Predicting Progression of STEC-HUS: Use of Shiga Toxin Subtype and Routine Laboratory Screening. Journal of the Pediatric Infectious Diseases Society, 14(4). https://doi.org/10.1093/jpids/piaf022
Vancouver
Maleknia L, Samiezade-Yazd Z, Luu X, Cranshaw M, Weintraub MR, Greenhow TL. Predicting Progression of STEC-HUS: Use of Shiga Toxin Subtype and Routine Laboratory Screening. Journal of the Pediatric Infectious Diseases Society. 2025;14(4). doi:10.1093/jpids/piaf022
BibTeX
@article{Maleknia2025,
author = {Maleknia, Lydia and Samiezade-Yazd, Zahra and Luu, Xing and Cranshaw, Matthew and Weintraub, Miranda Ritterman and Greenhow, Tara L},
title = {Predicting Progression of STEC-HUS: Use of Shiga Toxin Subtype and Routine Laboratory Screening},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2025},
volume = {14},
number = {4},
doi = {10.1093/jpids/piaf022}
}
EUVIMED